Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Shannon R. Morris"'
Autor:
Rajesh K. Malik, Petros Nikolinakos, Ralph V. Boccia, Konstantin H. Dragnev, Shannon R. Morris, Robert Hoyer, Donald A. Richards, Taofeek K. Owonikoko, A. Lowczak, Patrick J. Roberts, Vi Kien Chiu, J.T. Beck, Tibor Csoszi, Raid Aljumaily, Lowell L. Hart, I. Bulat, Maen A. Hussein, P. Sawrycki, Jessica A. Sorrentino, M. Maglakelidze, C.M. Rocha Lima, S. Adler, Jared Weiss, Zhao Yang, Joyce M Antal, S.R. Schuster, Wahid Hanna, M. Domine Gomez, Anne Y. Lai, John T. Hamm
Publikováno v:
Annals of Oncology
Background Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function duri
Autor:
Joyce M. Antal, Jennifer L. Gauvin, Carol Aghajanian, Jennifer J. Wheler, Ademi Santiago-Walker, Carla Kurkjian, Joanna Opalinska, Lillian L. Siu, Shubham Pant, Howard A. Burris, Shannon R. Morris, David S. Hong, Lee Ann Stayner, Jeffrey R. Infante, Katherine M. Bell-McGuinn
Publikováno v:
Investigational new drugs. 36(6)
BACKGROUND: We sought to determine the recommended phase II dose (RP2D) and schedule of GSK2141795, an oral pan-AKT kinase inhibitor. PATIENTS AND METHODS: Patients with solid tumors were enrolled in the dose-escalation phase. Pharmacokinetic (PK) an
Autor:
Thomas A. Lampkin, Emily K. Bergsland, Deborah A. Smith, Neeraj Agarwal, Razelle Kurzrock, Ruud van der Noll, Petronella O. Witteveen, Michael Durante, Joseph F. Kleha, Laurel M. Adams, Shannon R. Morris, Rahul Aggarwal, David S. Hong, Pamela N. Munster, E. Claire Dees, Jennifer M. Specht, Theresa L. Werner, Jan H.M. Schellens
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(8)
Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a first-in-human phase I study in patients with advanced solid tumors. Materials and Method
Autor:
Deborah A. Smith, Christine Chen, Joanna Opalinska, Shannon R. Morris, Andrew Spencer, Sung-Soo Yoon, Simon J. Harrison, Rakesh Kumar, Richard A. Brigandi, Jennifer Gauvin
Publikováno v:
Blood. 124(14)
The PI3K/AKT pathway is constitutively active in hematologic malignancies, providing proliferative and antiapoptotic signals and possibly contributing to drug resistance. We conducted an open-label phase 1 study to evaluate the maximum tolerated dose
Autor:
S. Gail Eckhardt, Gerald S. Falchook, Razelle Kurzrock, Carlos Becerra, Howard A. Burris, Keith T. Flaherty, Ngocdiep T. Le, Douglas J. DeMarini, Donna S. Cox, Vijay Gopal Reddy Peddareddigari, Sujatha Nallapareddy, Wells A. Messersmith, Leslie A. Fecher, Michael S. Gordon, Shannon R. Morris, Jeffrey R. Infante, Johanna C. Bendell, Yanmei Xu, Lowell L. Hart
Publikováno v:
The Lancet. Oncology. 13(8)
Summary Background Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this enzyme is a key anticancer target. Trametinib is a selective, orally administered MEK1/MEK2 inhibitor. We aimed to define the maximum tolerated dose
Autor:
Uday B. Dandamudi, Raymond J. Hohl, Brendan M. Johnson, Lionel D. Lewis, R. Timothy Webb, Laurel M. Adams, Sharon C. Murray, Shannon R. Morris, John W. Bauman, Elaina M. Gartner
Publikováno v:
Cancer chemotherapy and pharmacology. 67(4)
The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel.Fourteen cancer patients were enrolled in